mutant KRASG12C allosteric covalent inhibitor
orally efficacious in XG model
from optimization of literature starting point
J. Med. Chem. Feb. 5, 2020
AstraZeneca, Cambridge, UK
“compound 25”
KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)